Hampton, N.J., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) announced today the closing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. The shares began trading on the NASDAQ Global Market on February 13, 2015 under the ticker symbol "BLPH."
Leerink Partners LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. and FBR Capital Markets & Co. acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 13, 2015. Copies of the final prospectus relating to this offering may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at email@example.com, or by phone at (800) 808-7525, ext. 6142; or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling (631) 274-2806, or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse, one for the treatment of pulmonary arterial hypertension and a second for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease. Bellerophon's other program is bioabsorbable cardiac matrix, or BCM, which is being developed for the prevention of cardiac remodeling and subsequent chronic heart failure following acute myocardial infarction, commonly known as a heart attack.